S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
NASDAQ:AKRO

Akero Therapeutics Stock Forecast, Price & News

$21.34
-0.74 (-3.35 %)
(As of 10/15/2021 04:00 PM ET)
Add
Compare
Today's Range
$21.20
$22.34
50-Day Range
$18.65
$25.46
52-Week Range
$17.66
$34.87
Volume135,581 shs
Average Volume240,445 shs
Market Capitalization$743.96 million
P/E RatioN/A
Dividend YieldN/A
Beta0.56
30 days | 90 days | 365 days | Advanced Chart
Receive AKRO News and Ratings via Email

Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Akero Therapeutics logo

About Akero Therapeutics

Akero Therapeutics, Inc. operates as a cardio-metabolic nonalcoholic steatohepatitis company, which engages in developing pioneering medicines designed to restore metabolic balance and improve overall health. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKRO
Employees
22
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$7.45 per share

Profitability

Net Income
$-79.21 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$743.96 million
Next Earnings Date
11/11/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.05 out of 5 stars

Medical Sector

514th out of 1,361 stocks

Pharmaceutical Preparations Industry

242nd out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












Akero Therapeutics (NASDAQ:AKRO) Frequently Asked Questions

Is Akero Therapeutics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Akero Therapeutics stock.
View analyst ratings for Akero Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Akero Therapeutics?

Wall Street analysts have given Akero Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Akero Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Akero Therapeutics' next earnings date?

Akero Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Akero Therapeutics
.

How were Akero Therapeutics' earnings last quarter?

Akero Therapeutics, Inc. (NASDAQ:AKRO) released its quarterly earnings results on Thursday, August, 12th. The company reported ($0.83) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.72) by $0.11.
View Akero Therapeutics' earnings history
.

How has Akero Therapeutics' stock price been impacted by COVID-19?

Akero Therapeutics' stock was trading at $21.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AKRO shares have increased by 1.6% and is now trading at $21.34.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for AKRO?

7 brokerages have issued 1 year price objectives for Akero Therapeutics' shares. Their forecasts range from $40.00 to $81.00. On average, they expect Akero Therapeutics' stock price to reach $56.57 in the next twelve months. This suggests a possible upside of 165.1% from the stock's current price.
View analysts' price targets for Akero Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Akero Therapeutics' key executives?

Akero Therapeutics' management team includes the following people:
  • Andrew Cheng, President, Chief Executive Officer & Director
  • Jonathan Young, Chief Operating Officer & Executive Vice President (LinkedIn Profile)
  • William R. White, CFO, Treasurer, EVP & Head-Corporate Development
  • Timothy Rolph, Chief Scientific Officer
  • Reshma Shringarpure, Vice President-Clinical Research & Medical Affairs

What other stocks do shareholders of Akero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), (NGM) and VIVUS (VVUS).

When did Akero Therapeutics IPO?

(AKRO) raised $75 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

What is Akero Therapeutics' stock symbol?

Akero Therapeutics trades on the NASDAQ under the ticker symbol "AKRO."

How do I buy shares of Akero Therapeutics?

Shares of AKRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akero Therapeutics' stock price today?

One share of AKRO stock can currently be purchased for approximately $21.34.

How much money does Akero Therapeutics make?

Akero Therapeutics has a market capitalization of $743.96 million. The company earns $-79.21 million in net income (profit) each year or ($2.52) on an earnings per share basis.

How many employees does Akero Therapeutics have?

Akero Therapeutics employs 22 workers across the globe.

What is Akero Therapeutics' official website?

The official website for Akero Therapeutics is www.akerotx.com.

Where are Akero Therapeutics' headquarters?

Akero Therapeutics is headquartered at 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Akero Therapeutics?

Akero Therapeutics' mailing address is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 487-6488 or via email at [email protected].


This page was last updated on 10/15/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.